EvlaBio is a Swiss biotech company focused on the development of drug programs with significant unmet medical needs. Our clinical stage program is a fully monoclonal antibody effectively blocking the FGFR4/FGFR19 driven oncogenic pathway in HCC. According to first in human data, Anti-FGFR4 shows a highly attractive clinical profile not only in respect to the intended effects (tumor shrinkage) but also in relation to the side-effect profile. The develop of an imaging biomarker allows us better patient stratification and increase the probability of the overall clinical success rate. Our novel diagnostic biomarker and commercial strategy makes Anti-FGFR4 a highly attractive business case.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
